anti-VEGF: Definition, Uses, and Clinical Overview

anti-VEGF Introduction (What it is)

anti-VEGF refers to medicines that block vascular endothelial growth factor (VEGF).
VEGF is a natural signal in the body that can stimulate new blood vessel growth and leakage.
In the eye, anti-VEGF is commonly used to treat retinal diseases that involve abnormal vessels or fluid.
It is most often delivered as an injection into the eye by a retina specialist.

Why anti-VEGF used (Purpose / benefits)

The central goal of anti-VEGF treatment in ophthalmology is to reduce or stop damage caused by abnormal blood vessels and leakage inside the eye. In several retinal conditions, VEGF levels rise in response to stress (such as poor blood flow, inflammation, or tissue injury). Higher VEGF activity can lead to:

• Leakage of fluid into the retina (swelling), which can blur or distort central vision
• Growth of fragile, abnormal blood vessels that can bleed or scar, potentially threatening vision
• Ongoing retinal damage if swelling or bleeding persists

By blocking VEGF, anti-VEGF medicines are intended to dry retinal fluid, stabilize or improve vision in some cases, and reduce the risk of complications related to abnormal vessel growth.

From a patient perspective, the “problem it solves” is usually not a refractive issue (like needing glasses). Instead, anti-VEGF targets disease activity in the retina, particularly near the macula (the central retina responsible for detailed vision used for reading and recognizing faces). For many people, the benefit is improved ability to function visually—such as reading, driving, and recognizing faces—depending on the condition and the amount of existing retinal damage.

Benefits and goals are not identical for every diagnosis. Some conditions primarily involve macular swelling, while others involve new vessel growth. Treatment plans, expected response, and how long therapy is continued all vary by clinician and case.

Indications (When ophthalmologists or optometrists use it)

Anti-VEGF is typically used when an eye exam and retinal imaging suggest VEGF-driven fluid, bleeding, or abnormal new vessels. Common indications include:

• Neovascular (“wet”) age-related macular degeneration (AMD) with choroidal neovascularization (abnormal vessels under/within the retina)
• Diabetic macular edema (DME) (macular swelling from diabetes-related vascular leakage)
• Retinal vein occlusion (RVO) with macular edema (e.g., branch or central retinal vein occlusion)
• Proliferative diabetic retinopathy (PDR) and related neovascularization (abnormal new vessels from retinal ischemia)
• Myopic choroidal neovascularization (abnormal vessels associated with high myopia in some patients)
• Other causes of choroidal or retinal neovascularization, depending on diagnosis and specialist assessment

Optometrists often play a role in detection and referral, while ophthalmologists (particularly retina specialists) typically initiate and administer intravitreal anti-VEGF therapy.

Contraindications / when it’s NOT ideal

Anti-VEGF is not appropriate for every patient or every cause of blurred vision. Situations where it may be avoided, delayed, or approached differently can include:

• Suspected or active eye infection (for example, conjunctivitis or endophthalmitis risk), where injection may be postponed
• Significant intraocular inflammation (uveitis) in some contexts, depending on cause and clinician judgment
• Known hypersensitivity to the medication or formulation components (rare, but considered)
• When retinal fluid is not VEGF-driven, such as some inflammatory, tractional, or medication-related causes of swelling where other treatments may be more relevant
• Advanced scarring or atrophy in which the primary limitation is permanent tissue loss rather than active leakage (expected benefit may be limited)
• Predominantly tractional disease (for example, macular distortion from epiretinal membrane or vitreomacular traction), where surgery or other approaches may be more relevant
• Situations where an alternative treatment is preferred, such as laser photocoagulation, corticosteroid therapy, or surgery, depending on diagnosis and risk profile

These are general concepts. Whether anti-VEGF is “not ideal” often depends on the specific retinal findings, imaging results, and patient health context.

How it works (Mechanism / physiology)

Mechanism of action (high level)

VEGF is a signaling protein that can increase blood vessel permeability (leakiness) and promote growth of new blood vessels. Anti-VEGF medicines bind VEGF (or related pathways) and reduce VEGF signaling. In the retina, this commonly results in:

• Less leakage from abnormal or stressed retinal/choroidal vessels
• Reduced retinal swelling (macular edema)
• Suppression or regression of abnormal new vessels in some conditions

Relevant eye anatomy

Anti-VEGF therapy is mainly concerned with the retina and the choroid:

• The macula is the central retina responsible for fine detail vision.
• The retinal blood vessels supply the inner retina; diabetes and vein occlusions can damage them.
• The choroid lies beneath the retina and can be involved in abnormal vessel growth in wet AMD and other neovascular disorders.
• The vitreous is the gel filling the eye; anti-VEGF is often delivered into the vitreous so it can reach the retina.

Onset, duration, and reversibility

Anti-VEGF effects are not permanent. The medication gradually clears from the eye over time, and disease activity can recur. Many treatment plans require repeat dosing, especially early on, with intervals adjusted based on response. The timing of response and how long benefits last vary by clinician and case, the specific drug used, and the underlying disease process.

anti-VEGF Procedure overview (How it’s applied)

Anti-VEGF is a medication class rather than a standalone “procedure,” but it is most commonly administered as an intravitreal injection (an injection into the vitreous cavity). At a high level, care typically follows this workflow:

1. Evaluation / exam – Vision testing and symptom review
   – Dilated eye exam of the retina
   – Retinal imaging (commonly optical coherence tomography, and sometimes angiography) to assess fluid and vessels

2. Preparation – Discussion of the diagnosis, rationale, and expected monitoring pattern
   – Cleaning the eye area and using antiseptic to reduce infection risk
   – Numbing the eye with anesthetic drops and/or gel (methods vary)

3. Intervention – The medicine is injected into the eye in a controlled clinical setting
   – The injection itself is typically brief; technique details vary by clinician

4. Immediate checks – Brief assessment after the injection for comfort, vision changes, or pressure-related symptoms
   – Some clinics check intraocular pressure or optic nerve perfusion depending on protocol and patient factors

5. Follow-up – Repeat visits are common to monitor retinal fluid and vision
   – The number of injections and spacing over time can follow different strategies (see “Types / variations”)
   – Long-term monitoring is often needed for chronic conditions like wet AMD or diabetic eye disease

This overview is intentionally general. Exact steps, post-injection instructions, and follow-up intervals vary by clinician and case.

Types / variations

Anti-VEGF therapy varies by medication, dosing strategy, and in some settings, delivery approach.

Medication types (examples)

Commonly used intravitreal anti-VEGF agents include:

• Bevacizumab (often used off-label in eye care in many regions)
• Ranibizumab
• Aflibercept
• Brolucizumab
• Faricimab (targets VEGF-A and also angiopoietin-2, a related pathway in vascular stability)

Availability and approved indications vary by country and regulator, and medication choice often depends on the condition, clinician experience, patient-specific risk factors, and access considerations.

Dosing and monitoring strategies (examples)

Clinicians may use different scheduling approaches, including:

• Fixed-interval dosing (planned injections at set intervals)
• PRN (“as needed”) dosing based on imaging and exam findings
• Treat-and-extend where intervals may lengthen if the retina remains stable and shorten if disease activity returns

No single approach fits all patients. The plan is usually tailored to retinal imaging findings, symptoms, and prior response.

Other variations

• Biosimilars: In some regions, biosimilar versions of certain anti-VEGF agents may be available.
• Sustained-delivery concepts: Some therapies aim to reduce injection frequency via longer-acting formulations or delivery systems; appropriateness and availability vary.

Pros and cons

Pros:

• Targets a key driver of leakage and abnormal vessel growth in multiple retinal diseases
• Often improves or stabilizes retinal swelling visible on imaging
• Widely used with established clinical experience in retina care
• Can be dosed flexibly (fixed, PRN, treat-and-extend) depending on response
• Typically performed in an outpatient clinical setting
• May help reduce risk of bleeding or further damage from neovascularization in certain conditions

Cons:

• Often requires repeat treatments and ongoing monitoring for chronic diseases
• Involves intravitreal injection, which can be anxiety-provoking for some patients
• Potential eye-related risks exist, including infection (endophthalmitis), inflammation, bleeding on the eye surface, retinal tear/detachment, or pressure changes (risk levels vary)
• Some people experience temporary irritation (scratchy sensation, tearing, redness) after injection
• Vision outcomes depend on baseline damage; anti-VEGF cannot reverse all forms of retinal scarring or atrophy
• Cost and access can vary significantly by region, drug selection, and insurance coverage

Aftercare & longevity

After anti-VEGF treatment, the key concept is that many underlying retinal diseases are long-term conditions that can flare or quiet down over time. Outcomes and “how long it lasts” are influenced by multiple factors, including:

• Condition type and severity at diagnosis (for example, how much swelling, bleeding, or scarring is present)
• Baseline macular health (long-standing damage may limit visual recovery even if fluid improves)
• Consistency of monitoring (retinal imaging can detect recurrent fluid before major symptoms)
• Treatment strategy and interval chosen by the clinician, which may evolve over time
• Systemic health factors, especially in diabetic eye disease (overall vascular health can influence retinal stability)
• Coexisting eye conditions, such as cataract, glaucoma, or significant dry eye, which can affect vision and comfort but are not directly treated by anti-VEGF
• Medication selection and individual response, since some eyes respond differently to different agents

People often notice that vision can fluctuate with disease activity. A common practical theme is that anti-VEGF management is often framed as control and stabilization, with treatment frequency adjusted based on retinal findings rather than a one-time “cure.”

Alternatives / comparisons

Anti-VEGF is one major tool in retinal disease care, but it is not the only approach. Alternatives or adjuncts depend on the diagnosis and treatment goals.

• Observation / monitoring
• Sometimes appropriate when findings are mild, stable, or not clearly VEGF-driven.

• Monitoring may include vision checks and retinal imaging to watch for progression.

• Laser treatments

• Focal/grid laser may be used in selected cases of macular edema, though usage patterns vary with modern anti-VEGF therapy.

• Panretinal photocoagulation (PRP) is a well-established treatment for proliferative diabetic retinopathy; anti-VEGF may be used alongside or instead in certain scenarios, depending on follow-up reliability and clinical goals.

• Intravitreal corticosteroids

• Steroid injections or implants can reduce inflammation and vascular leakage and may be considered in some types of macular edema.

• Trade-offs can include cataract progression and intraocular pressure elevation in susceptible individuals.

• Vitrectomy surgery

• Considered when vision loss is driven by vitreous hemorrhage, traction, or retinal detachment risk, rather than primarily by VEGF-related leakage.

• Surgery addresses mechanical problems; anti-VEGF addresses biochemical signaling and vessel behavior. They can be complementary in selected cases.

• Systemic disease management

• While not an eye procedure, overall control of diabetes, blood pressure, and vascular risk factors is often part of comprehensive care for diabetic retinopathy and vein occlusions. The eye treatment plan may still be needed even with good systemic control.

Comparisons are rarely “either/or” forever. In real-world care, combinations and sequencing are common, and choices vary by clinician and case.

anti-VEGF Common questions (FAQ)

Q: Is anti-VEGF a drug or a procedure?
Anti-VEGF is a class of medications that block VEGF signaling. In eye care, these medicines are most commonly delivered by an intravitreal injection performed in a clinic setting. The injection is the delivery method; the medication is the therapy.

Q: Does an anti-VEGF injection hurt?
Most clinics use numbing drops and antiseptic preparation to reduce discomfort and infection risk. People often describe pressure or a brief pinch rather than sharp pain, but experiences vary. Mild irritation afterward is also commonly reported.

Q: How soon does anti-VEGF start working, and how long does it last?
Some eyes show reduced retinal fluid on imaging within weeks, but timing varies by condition and severity. The effect is not permanent, and repeat dosing is common because the medicine clears over time. The interval between treatments is individualized based on exam and imaging findings.

Q: Is anti-VEGF considered safe?
Anti-VEGF injections are widely used in retina care, and many patients receive them over long periods. However, no invasive eye treatment is risk-free; possible complications include infection inside the eye, inflammation, bleeding, retinal tear/detachment, and eye pressure changes. Systemic risks (such as clot-related events) are a consideration in certain patients, and clinicians weigh these factors case by case.

Q: Will I be able to drive after an anti-VEGF injection?
Vision may be temporarily blurry from dilating drops, the antiseptic, or normal post-injection irritation. Some people also notice new floaters or a transient hazy spot. Whether driving is appropriate depends on how the eye feels and how clearly the person can see afterward, and policies vary by clinic.

Q: Can I use screens or read after treatment?
Many people can resume light visual tasks when comfortable, but temporary blur or irritation can make reading harder on the day of treatment. Symptoms often settle as the surface irritation improves. Individual experiences vary.

Q: How many injections will I need?
There is no single number that applies to everyone. Some conditions require frequent injections early on, followed by less frequent maintenance, while others may need ongoing regular treatment. The plan is typically guided by retinal imaging and the presence or absence of recurring fluid or neovascular activity.

Q: What does anti-VEGF treat—does it fix cataracts or glasses prescription?
Anti-VEGF treats retinal diseases involving VEGF-driven leakage or abnormal vessels. It does not treat cataracts, glaucoma, or refractive error (nearsightedness, farsightedness, astigmatism). Vision can still be limited by other eye conditions even if retinal swelling improves.

Q: Why are there different anti-VEGF drugs, and does the choice matter?
Different agents vary in molecular design, binding targets, dosing intervals used in practice, and regulatory approvals. Some eyes respond better to one agent than another, and clinicians may switch medications if response is incomplete or side effects occur. Availability, access, and clinician preference can also influence selection.

Q: How much does anti-VEGF treatment cost?
Costs vary widely by country, healthcare system, insurance coverage, and the specific medication used. Clinic fees, imaging, and follow-up visit schedules also affect overall cost. A clinic’s billing team typically provides the most accurate estimate for a specific setting.